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Aravinda Chakravarti2,*Photo courtesy of ASHG.I want to begin by expressing my sincerest appreciation to
The American Society of Human Genetics (ASHG) for this
wonderful recognition and award; Vivian Cheung, Evan
Eichler, and Stanislas Lyonnet for their nominations; and
Evan Eichler for his very kind introduction. I want to thank
each of you who are here today and particularly my wife
and my daughters, who seldom get to hear what I have
been up to. I have been a member of ASHG since 1975,
have been attending its meetings since 1977, and have,
over the years, seen and heard the very best of our scien-
tists and clinicians receive this honor. I am both surprised
and delighted to stand beside them and hope to convince
you, over the next 30 min, of my laboratory’s deep fascina-
tion with human genetics.
I do not stand here either alone or unassisted. I am the
product of mentorship by many individuals, first while1This article is based on the address given by the author at themeeting of The A
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B.P. Adhikari, T.A. Davis, and R.L. Brahmachari), then
while trying to form my own research ideas in graduate
school (Drs. Masatoshi Nei and Alfred Knudson), and
finally while a beginning assistant professor at Pittsburgh
(Drs. C.C. Li and Haig Kazazian). Even when I thought I
knew which ideas to pursue, I was immeasurably helped
by a talented group of trainees without whom my accom-
plishments would have been meager. And then there have
been my numerous and diverse collaborators who have
taught me new corners of genetics.
So, where does one begin describing one’s journey into
understanding the molecular basis of complex genetic dis-
ease? I took my cue from rereading one of my favorite
authors, John Steinbeck, this past summer. Steinbeck be-
gins his 1945 Cannery Row as follows:
‘‘Cannery Row in Monterey in California is a poem, a
stink, a grating noise, a quality of light, a tone, a habit, a
nostalgia, a dream.(how can this) be set down alive?
When you collect marine animals there are certain flat
worms so delicate that they are almost impossible to cap-
ture whole, for they break and tatter under the touch.
You must let them ooze and crawl of their own will onto
a knife blade and then lift them gently into your bottle
of seawater.’’1
So, that’s what I will do: let the science from my labora-
tory ‘‘ooze and crawl of [its] own will’’ across time as my
ideas were developed, tested, and then refined. It is
possible that some might contest my narrative, but it is
my eyewitness account. From the beginning, the work
frommy laboratory had three cardinal features: it involved
both statistical and experimental approaches, both family-
based and population-based studies, and an evolutionary
perspective. But, to understand how my work developed,
I have to start at the beginning.
I was born and grew up in Calcutta, a much maligned
and blighted city in the Western imagination but one
with a long tradition of excellence, independence, and
dissent. Founded in 1690, it is an old city and has been
continually exposed to foreign cultures, starting with the
Mughals and then continuing with a variety of European
influences. Calcutta was the nucleus of the Bengal renais-
sance and was once the center of Indian education, sci-
ence, culture, and politics. Yes, I said ‘‘once’’: a reminder
that current success is ephemeral. It is a city wheremerican Society of HumanGenetics (ASHG) onOctober 25, 2013, in Boston,
.
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diversity is its DNA and its residents are interested in the
whole spectrum of the arts and humanities, science, and
politics. It is this city’s crucible that exposed me to more
possibilities than my mind could imagine.2
Like my two older brothers, I attended the Calcutta Boy’s
School (CBS), a Methodist missionary school very much
like the fictional English Public School in Lindsay Ander-
son’s movie If. CBS taught me to read widely, and I had
two dedicated biology and mathematics teachers who
taught me, throughMendel’s pea experiments, that empir-
ical observations are little without an underlying theory to
generalize them. After graduation, I was accepted into the
1970 undergraduate class at the Indian Statistical Institute
(ISI) into a program designed by P.C. Mahalanobis, a Cam-
bridge physicist turned statistician, and J.B.S. Haldane, the
polymath geneticist who renounced his British citizenship
to become an Indian in 1961 and came to work at the ISI.
Their joint imagination created a program of 4 years of
study in mathematics, statistics, and a variety of scientific
disciplines (including laboratory work) that represented
their broad scientific interests. Haldane had passed away
in 1964, but his ghost was still alive at the ISI when I began;
naturally, I focused on human genetics.2 I left the ISI in
1974 to pursue a PhD in human genetics at a new Univer-
sity of Texas Health Science Center at Houston graduate
school headed by Al Knudson, the 1978 president of
ASHG and the 1991 recipient of the Allan Award. I studied
with Masatoshi Nei (the doyen of neutral molecular evolu-
tion in the United States), who first made me work and
publish on theoretical aspects of genetic diversity (FST)
before he allowed me to graduate with a dissertation on
‘‘The Utility of Linked Marker Genes in Genetic Coun-
seling.’’ I was enamored then of how risk counseling would
change if disease-associated markers were available, that is,
by linkage disequilibrium (LD) rather thanmere linkage.3,4
I graduated in 1979 to my parents’ delight, and my father
wrote to say, ‘‘Today, your mother and I are so happy; two
of our children have PhDs, and the third is successful!’’
Subsequently, thinking I would learn genetic epidemi-
ology, I pursued 9 months of postdoctoral work with Ryk
Ward at The University of Washington, Seattle, but my
mind was elsewhere.
1979–1980 was the height of the recombinant DNA
period, even prior to the Botstein restriction-fragment-
length polymorphism (RFLP) paper,5 and I was afraid I
was unprepared. So, I accepted a teaching position at the
School of Public Health at the University of Pittsburgh
(no startup, no office, and no moving expenses) and
learned recombinant DNA technology in the laboratory
of another starting assistant professor, Jim Pipas, working
on SV40 large T antigen. The benefit of my teaching posi-
tion was that I had ‘‘free’’ time that allowed me to work
with C.C. Li at Pittsburgh and start a very fruitful and
long-term collaboration with Haig Kazazian and Stylianos
Antonarakis at Johns Hopkins. I prospered in Pittsburgh
but was recruited by Hunt Willard to Case Western Reserve
University in Cleveland, where my experimental phaseThe Amecontinued with even greater emphasis and I started my
genomics studies. I was eventually recruited to the Johns
Hopkins University School of Medicine in Baltimore to
direct the new McKusick-Nathans Institute of Genetic
Medicine in 2000 at a time when the genome sequence
was in hand and excitement over its applications to under-
standing human disease was paramount. To highlight my
laboratory’s scientific research, I will focus today on only
two aspects: how I came upon LD mapping and how I
used genomic approaches to understand the molecular
basis of Hirschsprung disease (HSCR). I apologize to the
many whose work I cannot describe here.
My focus on LD, or allelic association, arose from two
unrelated events. First, as an undergraduate, I took Hal-
dane’s advice that ‘‘one can do human genetics in India
without a lot of resources.’’6 Consequently, and knowing
too little to deter me, I designed, collected, and analyzed
familial phenotypic transmission of a simple observable
trait: hand clasping, routinely used inmany anthropomor-
phic surveys.7 I demonstrated that it is inherited in a near-
recessive manner and was surprised at its estimated high
allele frequency. The trait is common around the world,
and I was astounded (and still remain so) as to why such
a benign (useless?) trait is so variable. I thought perhaps
it was in allelic association with some beneficial mutation,
but that would require approaches that were not yet avail-
able and also unthinkable. Second, November 1978 was a
big month for me. Most importantly, I got married to my
wife, Shukti. But, the very same month, I came across
Kan and Dozy’s ground-breaking paper,8 which showed
three successes: identification of the first human DNA
polymorphism, its location in noncoding DNA, and its as-
sociation (LD) with the sickle mutation! This study was a
home run for me and opened many doors for me where
none existed. As of today, it is the paper that set our field
on a different trajectory.
The finding of an association between a disease muta-
tion and a specific marker, even outside a gene of interest,
was remarkable given that it immediately suggested a way
of mapping and identifying specific mutations: in reverse.
However, the scale of such mapping in humans was un-
known. I knew that in Drosophila large regions could be
in allelic association, but usually that was from suppressed
recombination within common chromosomal inversions;
the human genome was not known to harbor these and
was 30 times larger. To begin this LD-based reverse
genetics, I required a test case. The globins were one of
the most attractive genomic regions to tackle because their
mutations were known, their genes had been recently
cloned and mapped to individual chromosomes, and their
physical arrangements had been elucidated. A chance
encounter—my pursuit of data to understand molecular
patterns of LD and Haig Kazazian and Stylianos Antonara-
kis’s search to identify the molecular basis of b-thalasse-
mias—led to our collaboration on understanding the
patterns of diversity and association in the b-globin cluster.
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the first quantitative studies of LD in the human to give us
the scale of population recombination, demonstrate the
existence of haplotype ‘‘frameworks’’ (now called blocks),
and show that associations can dissipate over very short
distances. We inferred that meiotic recombination is
nonuniform in the human genome and mapped the loca-
tion of a putative recombination hotspot adjacent to the
b-globin-encoding gene.9 Although these ideas and obser-
vations were contested and very controversial when we
published them in 1984, they have stood the test of time
and are now commonplace, no doubt because of Mark
Daly’s subsequent studies on an interleukin cluster.10
The research I am not recounting, because it’s not my
own, is Haig and Stylianos’s great success in using the
b-globin frameworks for identifying a diverse set of molec-
ular thalassemia mutations; Haig received the Allan Award
in 2008 partly for these successes.11 I wanted to do the
same but in a situation where the gene for a phenotype
was unknown. In the 1980s, positional cloning had
come into its own, but all of the successes, except Stuart
Orkin and Lou Kunkel’s work on chronic granulomatous
disease,12 were based on a chromosomal lesion interrupt-
ing the coding sequence of the relevant gene. LD mapping
suggested a new approach provided that the mutant allele
was common. The perfect candidate was cystic fibrosis (CF)
given that its high incidence defied the mutation-selection
balance and suggested a single polymorphic (2%) mutant
allele maintained through overdominant selection. In
1985, at these meetings, Lap-Chee Tsui presented the first
DNA marker linked to CF. I met Lap-Chee at these meet-
ings, and we personally hit it off. This started my labora-
tory’s work, specifically by graduate student Tara Cox
Matise, on LD mapping in CF. Importantly, LD mapping
played a very critical role in the positional identification
of CFTR in 1989, and our elucidation of haplotypes in
CF-affected families uncovered a rich haplotype diversity,
of which the most frequent one harbored the now-famous
common mutant DF508.13 These studies would have been
impossible without Lap-Chee’s postdoctoral fellow Bat-
Sheva Kerem, who painstakingly generated tens of high-
frequency RFLP markers mapped relative to one another
(an LD map).
It is not surprising then that the CF studies, conducted in
an outbred rather than isolated population, imprinted
upon me the necessity of a high-frequency-polymorphism
map across the human genome for disease mapping; I was
not alone in this realization, given that Neil Risch, Eric
Lander, and Francis Collins had individually proposed
the same.14–16 The first of these maps was created by Eric
Lander’s group.17 However, it took completion of the
human genome sequence for a group of us—largely Francis
Collins, Eric Lander, David Altshuler, David Bentley, Peter
Donnelly and myself—to eventually champion, partici-
pate, and create the high-resolution maps of the HapMap
Project for common variants.18,19 Even prior to these
studies, it was clear that having a technology for screening
human genes directly for sequence variants, particularly328 The American Journal of Human Genetics 94, 326–333, March 6candidates for a given disorder, would be immensely help-
ful. One of my graduate students, Marc Halushka, worked
extensively with Jian-Bing Fan at Affymetrix to complete
such a study for candidate hypertension genes by using
the then novel array technology.20 These studies, and a
near-identical one from Eric Lander’s laboratory,21 were
published back to back in 1999 and showed how diverse
some human proteins are and that purifying selection on
nonsynonymous alterations is widespread, ideas now
commonplace. Consequently, by 2007, a near-complete
common-variant map including dense coverage of genes
was freely available through the HapMap project, a feature
that has changed complex disease mapping and its biology
forever. Indeed, with the completion of the 1000 Genomes
Project,22,23 which I also championed and participated in, I
cannot imagine a nongenomic genetics world.
Let me now turn to another of my laboratory’s parallel
developments that intellectually merged with the studies
I have described so far. Although my statistical training
and interests allowed me to be useful to others in genetic
studies of Mendelian disorders, I was far more interested
in understanding why some disorders are complex. R.A.
Fisher’s so-called synthesis in 1918 of the Biometrical-
Mendelian debate on the nature of genetic inheritance
was an artifice: it was a correct statistical description of
complex inheritance, but not a molecular one.24 So, it
was quite lucky that I came across an ideal opportunity: I
was asked to review the 1986Master’s thesis of a University
of Pittsburgh genetic-counseling student who had studied
the genetic epidemiology of HSCR.25 My simple reading of
the literature suggested that this disorder might be
amenable to genetic dissection using the evolving genetic
maps and positional cloning methods—perhaps not in
1986, but soon. What sealed the deal was the conversation
between the two senior committeemembers: the geneticist
lamenting that ‘‘we might not ever understand the under-
lying genes’’ and the pediatric surgeon arguing that ‘‘I am
no geneticist, but all I know is that I am repairing the chil-
dren of kids I repaired 25 years ago.that must count for
something.’’ In my mind, that counted for a lot!
HSCR (or congenital aganglionosis) is a neurodevelop-
mental defect of the enteric nervous system and is charac-
terized by a lack of nerve supply in segments of the gut,
leading to an absence of peristalsis and a functional intes-
tinal blockage.26 It is lethal if not surgically resected, and
today, rates of postoperative complication can be as high
as 30%. It is considered a multifactorial disorder and is
fairly frequent at 1 in 5,000 live births in newborns of
European ancestry but is twice as common in Asian in-
fants. HSCR also shows a curious sex bias in that four times
as many males as females are affected. The available ge-
netic data in 1986 showed some evidence of discrete
genetic loci given that numerous syndromic associations,
pedigrees in which HSCR segregated in a near-dominant
fashion, and recessive mouse models were already
known.26 To settle the issue, one of my MD-PhD students,
Judy Badner, performed statistical analysis of both the, 2014
extant published data and families we collected through
the Children’s Hospital of Pittsburgh to show four remark-
able features: its very high heritability, high prevalence of
associated anomalies, inverse relationship between the
extent of aganglionosis and sex ratio, and predicted ge-
netic etiologies in almost all cases!27 Moreover, nearly
15% of our severe long-segment cases were compatible
with incomplete dominance and were thus amenable to
genetic mapping using the just discovered microsatellite
markers.
In the period from 1993 to 1999, my group and others
accomplished precisely that. In 1993, Misha Angrist28 in
my group and Stan Lyonnet29 in Paris simultaneously pub-
lished themapping of a ‘‘dominant’’ form of HSCR to prox-
imal chromosome 10q, and within a year, Stan Lyonnet30
and Giovanni Romeo31 in Genoa identified deleterious
mutations in RET, encoding a receptor tyrosine kinase.
We followed with a report on diverse loss-of-function mu-
tations throughout the length of RET in all forms of HSCR
but found fewer coding mutations (at lower penetrance)
than others did.32 Nevertheless, we failed to find any RET
variants in the vast majority of the families we studied.
In parallel, Erik Puffenberger, another graduate student,
followed up on an extensive Old Order Mennonite kindred
in which HSCR segregated in an apparently ‘‘recessive’’
form by performing a genome-wide linkage study using
identity-by-descent sharing to implicate a locus on chro-
mosome 13q.33 Subsequently, we engaged in an exciting
collaboration with Masashi Yanagisawa at University of
Texas Southwestern to implicate a common (15%) hypo-
morphic missense substitution in the G-protein-coupled
receptor EDNRB.34 Interestingly, this variant showed
different degrees of penetrance in all three genotypes
and also showed interaction with a common RET haplo-
type. In quick succession, on the basis of our own studies
and the published biochemistry, we also demonstrated
substitutions in these two receptors’ ligands (namely
GDNF35 and EDN336) and, in collaboration with Bill
Pavan37 at the National Institutes of Health, in relevant
transcription factor SOX10. Mutations in SOX10 were
identified by Michele Goosens’ group38 the previous year
as a cause of Shah-Waardenburg syndrome, one of the
HSCR syndromes.
However, the mystery of the reduced penetrance of all of
the mutations identified still remained. We hypothesized
that full penetrance came about from the joint action of
both RET and EDNRB mutations. Given the commonality
of the EDNRB variant in Mennonites, in 2002, Minerva
Carrasquillo, then a graduate student in my laboratory,
performed one of the first microsatellite-marker-based
genome-wide association studies in the genetically isolated
Old Order Mennonites to demonstrate that strong epistasis
between RET and EDNRB mutations leads to higher pene-
trance.39 This work would have been less significant were
it not buttressed in this39 and subsequent work (by Andy
McCallion, then a postdoctoral fellow in my laboratory)
showing that these epistatic interactions could be fullyThe Amerecapitulated and lead to sex-biased expression of aganglio-
nosis in mice.40
Honestly, we were quite pleased because in a matter of
10 years, we had gone from a statistical description of
HSCR inheritance to knowing some of its molecular details
with precision and how the complex phenotype was
synthesized. We postulated a crude theory that HSCR re-
sulted from disrupted biochemical interactions either
within enteric neuroblasts or between neuroblasts and the
growth-factor-secreting cells of the gutmesenchyme. These
studies automatically led to a search formultiple raremuta-
tions within individual patients, and these we and others
described. A persistent feature of all of these studies was
the primacy of RET mutations in our patients. Our idea at
that timewas that HSCR patients had one primary RETmu-
tation and at least one other in a RET-dependent modifier.
Stacey Bolk Gabriel, not the confident person of today but
then a quiet graduate student in my laboratory, performed
two of these screens to map such modifiers.41,42 One of
these screens, in short-segment HSCR, was performed
with Remi Salomon, visiting from Stan Lyonnet’s labora-
tory in Paris, and clearly demonstrated the primacy of the
RET effect and the existence of at least two polymorphic
modifier loci; interestingly, these three loci recapitulated
both the HSCR incidence and recurrence risk.42
What was to come was even more surprising. Over time,
we found fewer and fewerRETcodingmutations; I reasoned
that our early data were biased upward given that we had
primarily collected multiplex families for linkage studies. I
hypothesized that if RET was involved in nearly every
HSCR patient and coding mutations were relatively rare,
then the remaining mutations must be in a neighboring
gene or a noncoding functional element. In 2005, in an
elegant series of experiments, my postdoctoral fellow
Eileen Emison and the newly independent Andy
McCallion, in collaborationwith Eric Green at theNational
Human Genome Research Institute and his postdoctoral
fellow Matthew Portnoy, performed old-fashioned se-
quencing of retrieved bacterial artificial clones containing
RET from 12 vertebrates and used comparative sequence
analysis to identify conserved noncoding elements.43 Betsy
Grice, a graduate student with Andy McCallion, did
functional analyses of 18 elements to identify numerous
potential RET enhancers, including those acting in gut
development in themouse.44Our data on sequencing these
enhancers in HSCR patients quickly identified a highly
polymorphic variant, called RETþ3, in the most potent
gut enhancer within intron 1 of RET as the causal site.43
To clarify its effect further, we collaborated in 2010 with
the International Hirschsprung Disease Consortium (with
principal investigators Salud Borrego [Sevilla], Isabella Cec-
cherini [Genoa], Aravinda Chakravarti [Baltimore], Robert
Hofstra [Rotterdam], Stanislas Lyonnet [Paris], and Paul
Tam [Hong Kong]) to publish a large study that clearly
demonstrated that this enhancer variant has unique prop-
erties and explainsmany features of HSCR’s complex inher-
itance: it had the highest frequency in the commonest andrican Journal of Human Genetics 94, 326–333, March 6, 2014 329
least severe cases (simplex males with short-segment dis-
ease) and the lowest frequency in the rarest and most
severe cases (multiplex females with long-segment disease);
interestingly, coding mutations had the precise opposite
relationship.45 Indeed, the enhancer genotypes varied in
risk by 200-fold. We also demonstrated by functional anal-
ysis that these effects arose from the abrogation of SOX10
binding at the enhancer.45
Our recent forays into the effects of RET enhancers are
even more intriguing. In unpublished work (presented at
this meeting) by two current postdoctoral fellows, Suman-
tra Chatterjee and Ashish Kapoor, we show that HSCR risk
is affected by two interacting noncoding elements each
imparting differential genetic risk.46 The second element
identified by a genome-wide association study is 125 kb
upstream of the transcription start site and is the predicted
binding site for a retinoic acid receptor, binding of which is
attenuated in the risk variant. We need to prove this
hypothesis functionally but believe in its likelihood given
that independent work by Robert Heuckeroth at
Washington University in St. Louis has shown that
vitamin A deficiency in a Ret heterozygote mouse leads to
aganglionosis.47 Therefore, RET genetic risk is affected by
at least two ‘‘shadow’’ enhancers. These two cis-regulatory
elements, which we show in collaboration with Len
Pennacchio and Eddy Rubin, are both active in the gut
and neurons, act at slightly different developmental time
points, and use the two different transcription factors
SOX10 and RARA. This is most likely the first description
in humans of complex genetic disease arising from two in-
teracting enhancers that, in the wild-type, provide exqui-
site control over enteric nervous system development.
To uncover all of HSCR’s associated genes, in the past
year, we have collaborated with Stacey Gabriel of the Broad
Institute of Harvard and MIT in Cambridge to complete
initial analysis of the exome sequences of a diverse group
of 189HSCRprobands. The chief protagonists of this exper-
iment in my laboratory have been two graduate students,
K.D. Nguyen and Tychele Turner, who have had consider-
able help from Courtney Berrios, my genetics counselor,
and Albee Ling. Compared to controls, HSCR genomes
show a ~1.5% excess of highly deleterious variants. To iden-
tify these specifically, we sought all genes withmore delete-
rious sequence variants thandictated by chance and further
narrowed this set to those with three or more deleterious
variants. We were astonished to net 363 genes! Is this list
credible? We strongly believe so given that both RET and
EDNRB were identified, as were mutations in six other
known HSCR-associated genes. Importantly, these 363
genes are highly enriched with those expressed in the em-
bryonic gut, as assessed by our RNA-sequencing studies in
mice at embryonic days 10.5 and 14.5 (over which time
the gut and enteric nervous system develop) and human
induced-pluripotent-stem-cell-derived neural crest cells.
In total, 225 of these genes are expressed in the gut, and
the functional categories enriched in this set are genes
affecting synaptogenesis, cytoskeletal architecture, and330 The American Journal of Human Genetics 94, 326–333, March 6the extracellular matrix. We also have begun analyzing
these exome sequences for copy-number variants (CNVs)
with Nik Krumm and Evan Eichler at the University of
Washington, Seattle.48 A further surprise is that HSCR pa-
tients have an excess of recurrent CNVs already known to
be associated with other neurodevelopmental disorders,
such as autism and epilepsy. In other words, these recurrent
CNVs might predispose to a broad neuronal dysfunction
whose specificity is producedwhen they reside in a genome
with other genes mutated in HSCR.
All of these are recent results that require validation,
confirmation, and peer review. I wanted to share them
with you to demonstrate that even a rare disease like
HSCR is the result of tens, if not hundreds, of genes and
has many valuable lessons to teach us. I will argue that
we are just beginning to ‘‘understand’’ this complex
genetic defect. But, before we do so, are any of the 225
gut-expressed genes with deleterious variants true? We
have begun the painstaking work of individually knocking
down their function in zebrafish embryos, an excellent
model for studying the migration of enteric neurons, to
assess their phenotype. The first class we have focused on
is a set of genes likely affecting neuronal ubiquitylation
by showing that loss of function of UBR4, which encodes
an E3 ubiquitin ligase, clearly affects normal ganglionosis
in zebrafish and demonstrates strong epistasis with RET.
So, what have we learned? We now know the identity of
the many genes that are mutant in HSCR and are begin-
ning to understand how they bring about their effects.
Enteric nervous system development is highly dependent
on a group of early transcription factors, such as PAX3
and SOX10, and two key signaling molecules, RET and
EDNRB. Normal development requires passage through
this rate-limiting developmental step, which is why delete-
rious coding variants in these genes are associated with
severe disease. Weaker mutations, such as the enhancer
alleles I spoke of, might allow passage through this step,
which is why less severe and common forms of HSCR
occur from the joint action of these weaker deleterious
alleles with additional mutations in subsequent develop-
mental processes, such as in the formation of neuromus-
cular junctions or in neuronal activity per se. Quite impor-
tantly, HSCR is not exclusively a neuronal disease given
that mutations in genes affecting nonneuronal tissue,
such as the extracellular matrix, have now been identified.
I have no doubt that human genetics will prove its worth
in the subsequent few years to further solve these puzzles.
None of the work I described would have been possible
without a strong belief in the awesome power of human
genetics, the principles of evolution, and my deep, deep
respect for basic and fundamental research. Many years
ago, the great biochemist Arthur Kornberg laid down his
ten commandments, such as the one on evolution:
‘‘What’s true for E. coli is true for elephants; what’s not
true for E. coli is simply not true.’’49 He also humorously
wrote that Moses, while coming down from the mountain
after his meeting with the Almighty, carried down three, 2014
tablets, one of which broke but contained the most impor-
tant 11th commandment: ‘‘Thou shalt respect basic
research.’’49 In these days, when translation of our science
is imminent, the need for basic research is even greater, an
aspect that I believe is given insufficient support.
Let me end with a few more thanks. First, to my parents,
now both deceased. They did much more than give me
their genomes; they were giants and have bequeathed to
my brothers and me their lives as lessons. Second, to my
beautiful wife and our two lovely daughters. I thank
them for their daily support and love and all that it takes
to make our house a home; our lives are sometimes chaotic
but always interesting. My wife, Shukti, is a noted cell and
molecular biologist of her own accord, and I have been
lucky to have learned ‘‘real’’ biology from her through
osmosis over our 35 years together. Also, thanks to this
country and the ASHG, which have given me so many op-
portunities. However, this has not come without some
pain. The life of immigrants, with the absence of our lan-
guage, culture, and family, is largely an unobserved one
to most of you and carries with it a permanent sense of
dislocation and loss. Still, it has been a great and worth-
while journey, and I am not about to turn back. I will
end by quoting the last paragraph from the last chapter
of the book Interpreter of Maladies, written by one of the
best short-story writers in the United States, the Bengali
American Jhumpa Lahiri. She writes in the ‘‘Third and
Final Continent’’ of a protagonist, modeled after her father
and similar to mine, who left Calcutta to study in England
and then at the Massachusetts Institute of Technology in
this very city. The year is 1969, and the protagonist rents
a room in the home of the 103-year-old Mrs. Croft, who
simply cannot believe that man has landed on the
moon. It is to this simple beginning on which he reflects:
‘‘In my son’s eyes I see the ambition that had first hurled
me across the world. In a few years he will graduate and
pave his way, alone and unprotected. But I remind myself
that he has a father who is still living, a mother who is
happy and strong. Whenever he is discouraged, I tell him
that if I can survive on three continents, then there is no
obstacle he cannot conquer. While the astronauts, heroes
forever, spent mere hours on the moon, I have remained
in this new world for nearly 30 years. I know that my
achievement is quite ordinary. I am not the only man to
seek his fortune far from home, and certainly I am not
the first. Still, there are times when I am bewildered by
eachmile I have traveled, eachmeal I have eaten, each per-
son I have known, each room in which I have slept. As
ordinary as it all appears, there are times when it is beyond
my imagination.’’50
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